戴纳基宣布,其针对1型强直性肌营养不良症的在研药物Z-Basivarsen,其关键性临床试验Achieve的注册扩展队列已完成患者入组工作。
该进展标志着药物开发进程中的一个重要节点,为后续数据收集与分析奠定了基础。
戴纳基宣布,其针对1型强直性肌营养不良症的在研药物Z-Basivarsen,其关键性临床试验Achieve的注册扩展队列已完成患者入组工作。
该进展标志着药物开发进程中的一个重要节点,为后续数据收集与分析奠定了基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.